Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Judgmentalism applied to patients from poor and marginalized communities exacerbates health inequity and illuminates the importance of contextualizing a patient’s care.
AMA J Ethics. 2021;23(2):E91-96. doi:
10.1001/amajethics.2021.91.
Some refugees’ illness experiences preclude them from testifying and accurately representing their own interests during asylum adjudication proceedings.
AMA J Ethics. 2021;23(2):E132-139. doi:
10.1001/amajethics.2021.132.